» Articles » PMID: 37064093

Single and Combined Use of the Platelet-lymphocyte Ratio, Neutrophil-lymphocyte Ratio, and Systemic Immune-inflammation Index in Gastric Cancer Diagnosis

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Apr 17
PMID 37064093
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) are markers for systemic inflammatory responses and have been shown by numerous studies to correlate with the prognosis of gastric cancer (GC). However, the diagnostic value of these three markers in GC is unclear, and no research has examined them in combination. In this study, we investigated the value of the PLR, NLR, and SII individually or in combination for GC diagnosis and elucidated the connection of these three markers with GC patients' clinicopathological features.

Methods: This retrospective study was conducted on 125 patients diagnosed with GC and 125 healthy individuals, whose peripheral blood samples were obtained for analysis. The preoperative PLR, NLR, and SII values were subsequently calculated.

Results: The results suggest that the PLR, NLR, and SII values of the GC group were considerably higher than those of the healthy group (all P ≤ 0.001); moreover, all three parameters were notably higher in early GC patients (stage I/II) than in the healthy population. The diagnostic value of each index for GC was analyzed using receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) calculation. The diagnostic efficacy of the SII alone (AUC: 0.831; 95% confidence interval [CI], 0.777-0.885) was expressively better than those of the NLR (AUC: 0.821; 95% CI: 0.769-0.873, P = 0.017) and PLR (AUC: 0.783; 95% CI: 0.726-0.840; P = 0.020). The AUC value of the combination of the PLR, NLR, and SII (AUC: 0.843; 95% CI: 0.791-0.885) was significantly higher than that of the combination of the SII and NLR (0.837, 95% CI: 0.785-0.880, P≤0.05), PLR (P = 0.020), NLR (P = 0.017), or SII alone (P ≤ 0.001). The optimal cut-off values were determined for the PLR, NLR, and SII using ROC analysis (SII: 438.7; NLR: 2.1; PLR: 139.5). Additionally, the PLR, NLR, and SII values were all meaningfully connected with the tumor size, TNM stage, lymph node metastasis, and serosa invasion (all P ≤ 0.05). Elevated levels of the NLR and SII were linked to distant metastasis (all P ≤ 0.001).

Discussion: These data suggest that the preoperative PLR, NLR, and SII could thus be utilized as diagnostic markers for GC or even early GC. Among these three indicators, the SII had the best diagnostic efficacy for GC, and the combination of the three could further improve diagnostic efficiency.

Citing Articles

Value of brief hematological characteristics in differentiating carcinoembryonic-antigen-negative colorectal cancer from benign colorectal diseases.

Yi L, Lao X, Lu L, Zhu C, Zhou D, Li S World J Gastrointest Surg. 2025; 17(2):101403.

PMID: 40061991 PMC: 11885996. DOI: 10.4240/wjgs.v17.i2.101403.


Development and validation of a nomogram model for predicting overall survival in patients with gastric carcinoma.

Liang G, Li X, Hu Z, Xu Q, Wu F, Wu X World J Gastrointest Oncol. 2025; 17(2):95423.

PMID: 39958550 PMC: 11755997. DOI: 10.4251/wjgo.v17.i2.95423.


Diagnostic implications of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammatory index for gastric carcinoma.

Wu H, Ying X, Lv L, Hu J World J Gastrointest Surg. 2025; 17(1):100130.

PMID: 39872777 PMC: 11757178. DOI: 10.4240/wjgs.v17.i1.100130.


The Clinical Value of the Combined Detection of Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Prognostic Nutritional Index (PNI) in Early Diagnosis of Gastric Cancer.

Zheng J, Zheng L, Wang X, Mao X, Wang Q, Yang Y J Inflamm Res. 2025; 18():813-826.

PMID: 39845022 PMC: 11752871. DOI: 10.2147/JIR.S496703.


Advancing prognostic precision in gastric cancer with an immunoinflammatory index.

Zhang H, Wang G, Sun S, Yuan L World J Gastroenterol. 2024; 30(44):4754-4758.

PMID: 39610779 PMC: 11580602. DOI: 10.3748/wjg.v30.i44.4754.


References
1.
Jiang L, Yang K, Guan Q, Chen Y, Zhao P, Tian J . Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis. J Clin Gastroenterol. 2014; 49(5):387-94. DOI: 10.1097/MCG.0000000000000212. View

2.
Hirahara N, Matsubara T, Fujii Y, Kaji S, Kawabata Y, Hyakudomi R . Comparison of the prognostic value of immunoinflammation-based biomarkers in patients with gastric cancer. Oncotarget. 2020; 11(27):2625-2635. PMC: 7343633. DOI: 10.18632/oncotarget.27653. View

3.
Peng H, Yang L, He B, Pan Y, Ying H, Sun H . Combination of preoperative NLR, PLR and CEA could increase the diagnostic efficacy for I-III stage CRC. J Clin Lab Anal. 2016; 31(5). PMC: 6816914. DOI: 10.1002/jcla.22075. View

4.
He K, Si L, Pan X, Sun L, Wang Y, Lu J . Preoperative Systemic Immune-Inflammation Index (SII) as a Superior Predictor of Long-Term Survival Outcome in Patients With Stage I-II Gastric Cancer After Radical Surgery. Front Oncol. 2022; 12:829689. PMC: 8918673. DOI: 10.3389/fonc.2022.829689. View

5.
Qian S, Golubnitschaja O, Zhan X . Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J. 2019; 10(4):365-381. PMC: 6882964. DOI: 10.1007/s13167-019-00194-x. View